Laboratory and clinical aspects of human papillomavirus testing

Critical Reviews in Clinical Laboratory Sciences

Volumn 49, Issue 4, 2012, Pages 117-136

  Chan, Paul K S ^a   Picconi, María Alejandra ^b   Cheung, Tak Hong ^a   Giovannelli, Lucia ^c   Park, Jong Sup ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c UNIVERSITY OF PALERMO   (Italy)

^d The Catholic University of Korea   (South Korea)

Author keywords

Biomarker; Cervical cancer; Cervical intraepithelial neoplasia; Cervical screening; Co test; Colposcopy; Epidermodysplasia verruciformis; Human papillomavirus; Oropharyngeal cancer; Penile cancer; Skin cancer; Triage; Vaginal cancer; Vulvar cancer; Warts

Indexed keywords

VIRUS DNA; VIRUS PROTEIN; WART VIRUS VACCINE;

ANUS CANCER; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DNA DETERMINATION; EPIDERMODYSPLASIA VERRUCIFORMIS; GENITAL TRACT INFECTION; HUMAN; INTERMETHOD COMPARISON; MELANOMA; MOUTH INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OROPHARYNX CANCER; PENIS CANCER; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SKIN INFECTION; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VULVA CANCER; WART VIRUS;

CLINICAL LABORATORY TECHNIQUES; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

HUMAN PAPILLOMAVIRUS;

EID: 84865490951     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2012.707174     Document Type: Review

References (276)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-79.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
3. Syrjen S. Current concepts on human papillomavirus infections in children. APMIS 2010;118:494-509.
4. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31. (Pubitemid 41831374)
5. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: human papillomavirus-mediated carcinogenesis. Head Face Med 2010;6:14.
6. Feller L, Wood NH, Khammissa RA, Lemmer J. Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head Face Med 2010;6:15.
7. Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis: update 2008. Curr Opin Otolaryngol Head Neck Surg 2008;16:536-542.
8. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 2009;31:561-573.
9. Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 2008;43:353-360.
10. Handisurya A, Schellenbacher C, Kirnbauer R. Diseases caused by human papillomaviruses (HPV). J Dtsch Dermatol Ges 2009;7:453-466; quiz 466, 467.
11. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;31:52-56.
12. zur Hausen H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009;384:260-265.
13. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003;16:1-17. (Pubitemid 36114705)
14. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116:1167-1173.
15. Forslund O, Antonsson A, Nordin P, Stenquist B, Hansson BG. A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. J Gen Virol 1999;80:2437-2443. (Pubitemid 29408373)
16. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 2007;127:116-119. (Pubitemid 46005668)
17. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000;74:11636-11641. (Pubitemid 32222312)
18. Mammas IN, Sourvinos G, Spandidos DA. Human papilloma virus (HPV) infection in children and adolescents. Eur J Pediatr 2009;168:267-273.
19. Kirnbauer R, Lenz P, Okun MM. Human Papillomavirus. In: Bolognia J, Jorizzo J, Rapini R, ed. Dermatology, Vol. 1. London: Mosby, 2008:1183-1198.
20. McLaughlin JS, Shafritz AB. Cutaneous warts. J Hand Surg Am 2011;36:343-344.
21. Syrjen KJ. Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland. Scand J Infect Dis Suppl 2009;107:3-32.
22. Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009;44:111-114.
23. Oon SF, Winter DC. Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. J Med Screen 2010;17:44-49.
24. Hsueh PR. Human papillomavirus, genital warts, and vaccines. J Microbiol Immunol Infect 2009;42:101-106.
25. Ghaemmaghami F, Nazari Z, Mehrdad N. Female genital warts. Asian Pac J Cancer Prev 2007;8:339-347.
26. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450-454.
27. Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, Abramson AL. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and-11. APMIS 2010;118:455-470.
28. Tasca RA, Clarke RW. Recurrent respiratory papillomatosis. Arch Dis Child 2006;91:689-691. (Pubitemid 44197114)
29. Feller L, Khammissa RA, Wood NH, Malema V, Meyerov R, Lemmer J. Focal epithelial hyperplasia (Heck disease) related to highly active antiretroviral therapy in an HIV-seropositive child. A report of a case, and a review of the literature. SADJ 2010;65:172-175.
30. Feller L, Khammissa RA, Wood NH, Marnewick JC, Meyerov R, Lemmer J. HPV-associated oral warts. SADJ 2011;66:82-85.
31. Gonzez JV, Gutirez RA, Keszler A, Colacino Mdel C, Alonio LV, Teyssie AR, Picconi MA. Human papillomavirus in oral lesions. Medicina (B Aires) 2007;67:363-368. (Pubitemid 47381197)
32. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-350. (Pubitemid 37328947)
33. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health 2010;7:244-252.
34. Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32: 579-581. (Pubitemid 35435168)
35. Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006;18: 362-374. (Pubitemid 44511885)
36. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009;73:348-370.
37. Sterling JC. Human papillomaviruses and skin cancer. J Clin Virol 2005;32:S67-71. (Pubitemid 40332591)
38. Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers 2010;29: 199-206.
39. Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, Nordin P, et al; Viraskin Study Group. Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007;196:876-883. (Pubitemid 47378937)
40. Patel AS, Karagas MR, Perry AE, Nelson HH. Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol 2008;128:2888-2893.
41. Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, Raugi GJ, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008;128:1409-1417. (Pubitemid 351693210)
42. Akg B, Cooke JC, Storey A. HPV-associated skin disease. J Pathol 2006;208:165-175. (Pubitemid 43126110)
43. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009;27:141-150.
44. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 (Suppl 3):S3/11-25.
45. Muz N, CastellsaguX, de Gonzez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 (Suppl 3): S3/1-10.
46. Chao A, Chen TC, Hsueh C, Huang CC, Yang JE, Hsueh S, et al. Human papillomavirus in vaginal intraepithelial neoplasia. Int J Cancer 2012;131:E259-E268.
47. Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997;90:748-754. (Pubitemid 27449727)
48. Tumours of the vulva. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003: 313-333.
49. Junge J, Poulsen H, Horn T, Hding U, Lundvall F. Human papillomavirus (HPV) in vulvar dysplasia and carcinoma in situ. APMIS 1995;103:501-510.
50. Alonso I, Fust V, del Pino M, Castillo P, Torn̈A, Fust P, et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol Oncol 2011;122:509-514.
51. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-280. (Pubitemid 38890829)
52. Dietz CA, Nyberg CR. Genital, oral, and anal human papillomavirus infection in men who have sex with men. J Am Osteopath Assoc 2011;111(3 Suppl 2):S19-S25.
53. Palefsky J. Can HPV vaccination help to prevent anal cancer? Lancet Infect Dis 2010;10:815-816.
54. Smith PG, Kinlen LJ, White GC, Adelstein AM, Fox AJ. Mortality of wives of men dying with cancer of the penis. Br J Cancer 1980;41:422-428. (Pubitemid 10131248)
55. Picconi MA, Eij AM, Dist ano AL, Pueyo S, Alonio LV, Gorostidi ST, et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol 2000;61:65-69. (Pubitemid 30191227)
56. Palefsky JM. Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010;46(4 Suppl):S12-S19.
57. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Prev Med 2011;53 (Suppl 1):S36-S41.
58. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
59. WHO. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. Geneva, Switzerland: World Health Organization 2008;1-42.
60. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004;109:418-424. (Pubitemid 38252771)
61. Arbyn M, CastellsaguX, de SanjosS, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-2686.
62. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
63. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294-4301.
64. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-619. (Pubitemid 351264356)
65. Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756-1772.
66. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-789.
67. Syrjen S, Lodi G, von B́tzingsl̈en I, Aliko A, Arduino P, Campisi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis 2011;17 (Suppl 1):58-72.
68. Toner M, O'Regan EM. Head and neck squamous cell carcinoma in the young: a spectrum or a distinct group? Part 1. Head Neck Pathol 2009;3:246-248.
69. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
70. Howley PM, Lowy DR. Papillomavirus. In: Knipe DM, Howley PM, et al., eds: Fields Virology, Vol. 2. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2007: 2299-2354.
71. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004;68:362-372. (Pubitemid 38756870)
72. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005;32 (Suppl 1):S7-S15. (Pubitemid 40332584)
73. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into viruslike particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-12184. (Pubitemid 23004809)
74. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991;185:251-257.
75. Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011;269:5-9.
76. Villa LL. HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett 2011;305:106-112.
77. Frazer IH. Cervical cancer vaccine development. Sex Health 2010;7:230-234.
78. Tumban E, Peabody J, Peabody DS, Chackerian B. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011;6:e23310.
79. Conway MJ, Cruz L, Alam S, Christensen ND, Meyers C. Crossneutralization potential of native human papillomavirus N-terminal L2 epitopes. PLoS One 2011;6:e16405.
80. Caldeira Jdo C, Medford A, Kines RC, Lino CA, Schiller JT, Chackerian B, Peabody DS. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010;28:4384-4393.
81. Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010;23:70-75.
82. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
83. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505. (Pubitemid 23335075)
84. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994;8:666-677. (Pubitemid 24116761)
85. Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995;55:4420-4424.
86. Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996;13:427-431. (Pubitemid 26334876)
87. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-2072. (Pubitemid 28323879)
88. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998;17:2943-2954. (Pubitemid 29012197)
89. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996;380:79-82. (Pubitemid 26076241)
90. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996;56: 2886-2890. (Pubitemid 26199724)
91. Dyson N, Howley PM, M?ger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-937. (Pubitemid 19066153)
92. Dyson N, Guida P, M̈ger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992;66:6893-6902.
93. Arroyo M, Bagchi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2Fcyclin A complex. Mol Cell Biol 1993;13:6537-6546. (Pubitemid 23292648)
94. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997;11:2090-2100. (Pubitemid 27369103)
95. Smotkin D, Wettstein FO. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 1986;83:4680-4684. (Pubitemid 16075465)
96. Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH, Chen SL. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci. 2001;8:206-213. (Pubitemid 32268558)
97. Maufort JP, Shai A, Pitot HC, Lambert PF. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res 2010;70:2924-2931.
98. Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo MS, Borzacchiello G. Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 2011;10:140.
99. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110:525-541. (Pubitemid 43736116)
100. Romanczuk H, Thierry F, Howley PM. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol 1990;64:2849-2859. (Pubitemid 20171275)
101. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 2006;11:2286-2302. (Pubitemid 43822560)
102. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPVmediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-164. (Pubitemid 43126109)
103. de Villiers EM, Bernard HU, Broker T, Delius H, zur Hausen H. Family Papillomaviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus Taxonomy. Eighth Report of the International Committee on Taxonomy of Viruses. San Diego: Elsevier Academic Press, 2005:239-255.
104. Family Papillomaviridae. In: Van Regenmortel MH, Fauquet CM, Bishop DH, Carstens EB, Estes MK, Lemon SM, et al., eds. Virus Taxonomy. Seventh Report of the International Committee for the Taxonomy of Viruses. San Diego: Academic Press, 2000: 247-251.
105. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27. (Pubitemid 38737395)
106. Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson AL, et al. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol 2005;79:13630-13640. (Pubitemid 41508175)
107. Chan PK, Luk AC, Park JS, Smith-McCune KK, Palefsky JM, Konno R, et al. Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis 2011;203:1565-1573.
108. Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011;6:e20183.
109. Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD. Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 2009;83:1443-1455.
110. Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, et al. Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18. Virology 2005;340:95-104. (Pubitemid 41191181)
111. Raiol T, Wyant PS, de Amorim RM, Cerqueira DM, Milanezi NG, Brido Mde M, et al. Genetic variability and phylogeny of the high-risk HPV-31,-33,-35,-52, and-58 in central Brazil. J Med Virol 2009;81:685-692.
112. Muz N, Bosch FX, de SanjosS, Herrero R, CastellsaguX, Shah KV, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527. (Pubitemid 36159887)
113. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84. (Pubitemid 40725441)
114. Herrero R. Human papillomavirus (HPV) vaccines: limited crossprotection against additional HPV types. J Infect Dis 2009;199:919-922.
115. Wheeler CM, CastellsaguX, Garland SM, Szarewski A, Paavonen J, Naud P, et al.; for the HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-110.
116. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, CastellsaguX, et al; for the HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-110.
117. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-935.
118. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-944.
119. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
120. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. (Pubitemid 40450709)
121. Chow LT, Broker TR. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin Dermatol 1997;15:217-227. (Pubitemid 27229998)
122. Dollard SC, Wilson JL, Demeter LM, Bonnez W, Reichman RC, Broker TR, Chow LT. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev 1992;6:1131-1142.
123. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992;257:971-973.
124. Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24 (Suppl 1):S16-S22.
125. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009;384: 410-414.
126. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211-222. (Pubitemid 38339087)
127. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432-436. (Pubitemid 34671244)
128. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-336. (Pubitemid 40563172)
129. Chang YE, Laimins LA. Microarray analysis identifies interferoninducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 2000;74:4174-4182. (Pubitemid 30214423)
130. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferationassociated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-4296. (Pubitemid 32410141)
131. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M, et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004;64:6766-6774. (Pubitemid 39297940)
132. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-499. (Pubitemid 24111004)
133. Wikstr A, van Doornum GJ, Quint WG, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995;76:529-539.
134. Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee SK, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995;172:11-18.
135. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919. (Pubitemid 30416152)
136. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983-3985.
137. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-520.
138. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46(Suppl 3):S1-S4.
139. l̈incz A. Hybrid capture method for detection of human papillomavirus DNA in clinical specimens: a tool for clinical management of equivocal Pap smears and for population screening. J Obstet Gynaecol Res 1996;22:629-36.
140. Peyton CL, Schiffman M, Lorincz AT, Hunt WC, Mielzynska I, Bratti C, et al. Comparison of PCR-and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. Clin Microbiol 1998;36:3248-3254. (Pubitemid 28476174)
141. Castle PE, Schiffman M, Burk RD, Wacholder S, Hildesheim A, Herrero R, et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002;11:1394-1399. (Pubitemid 35340375)
142. Ting Y, Manos M. Detection and typing of genital human papillomaviruses. In: Innis M, Gelfand D, Sninsky J, White T, eds. PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press, 1990:356-366.
143. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutl̈ F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361. (Pubitemid 30043317)
144. Estrade C, Menoud PA, Nardelli-Haefliger D, Sahli R. Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol 2011;49:3474-3481.
145. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76:1057-1062.
146. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5 +GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 highrisk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-795. (Pubitemid 27083888)
147. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 2006;118:243-245. (Pubitemid 41681605)
148. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-1739. (Pubitemid 28550661)
149. Jeney C, Tak̈s T, Sebe A, Schaff Z. Detection and typing of 46 genital human papillomaviruses by the L1F/L1R primer system based multiplex PCR and hybridization. J Virol Methods 2007;140:32-42. (Pubitemid 46201702)
150. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077-1085.
151. Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, Cheng AF. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999;59:232-238. (Pubitemid 29407287)
152. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
153. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010;10:550-560.
154. McLaughlin-Drubin ME, M̈ger K. Oncogenic activities of human papillomaviruses. Virus Res 2009;143:195-208.
155. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, Mansur CP, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 1999;73:7297-7307. (Pubitemid 29383212)
156. Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010;118:471-493.
157. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010;40:1-13.
158. Ganguly N, Parihar SP. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009;34:113-123.
159. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384:324-334.
160. Gnanamony M, Peedicayil A, Subhashini J, Ram TS, Rajasekar A, Gravitt P, Abraham P. Detection and quantitation of HPV 16 and 18 in plasma of Indian women with cervical cancer. Gynecol Oncol 2010;116:447-451.
161. Flores-Munguia R, Siegel E, Klimecki WT, Giuliano AR. Performance assessment of eight high-throughput PCR assays for viral load quantitation of oncogenic HPV types. J Mol Diagn 2004;6:115-124. (Pubitemid 38578987)
162. Chow LT, Broker TR, Steinberg BM. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010;118:422-449.
163. Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes.
164. Chow LT, Broker TR. Mechanisms and regulation of papillomavirus DNA replication. In: Campo MS, ed. Recent Advances in Papillomavirus Research. Norwich, UK: Caister Academic Press, 2006:53-71.
165. Sotlar K, Selinka HC, Menton M, Kandolf R, B́tmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998;69:114-121. (Pubitemid 28246996)
166. Sotlar K, Stubner A, Diemer D, Menton S, Menton M, Dietz K, et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004;74:107-116. (Pubitemid 38988867)
167. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908-915. (Pubitemid 40824665)
168. Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A, et al. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 2006;29:705-711.
169. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010;48:2779-2785.
170. Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599-2605. (Pubitemid 46788025)
171. Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, Di Franco A, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol 2009;47:3895-3901.
172. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45 (Suppl 1):S55-S61.
173. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, Penaranda G, Blanc B. Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 2010;47:177-181.
174. Burger EA, Korn̈ H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011;120:430-438.
175. Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, M̈ler-Holzner E, et al. Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. Virology 2011;409:54-68.
176. Ressler S, Scheiden R, Dreier K, Laich A, M̈ler-Holzner E, Pircher H, et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007;13:7067-7072. (Pubitemid 350276889)
177. Franco EL, Duarte-Franco E, Rohan TE. Evidence-based policy recommendations on cancer screening and prevention. Cancer Detect Prev 2002;26:350-361. (Pubitemid 36035380)
178. Sasieni P, Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. BMJ 1999;318:1244-1245. (Pubitemid 29210053)
179. van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008;122:1854-1858. (Pubitemid 351413434)
180. Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer 2005;92:1800-1802. (Pubitemid 40756496)
181. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996;73:1001-1005. (Pubitemid 26116757)
182. WHO/ICO Information Centre on HPV and Cervical Cancer. HPV and cervical cancer in the 2007 report. Vaccine 2007;25:C1-C230.
183. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-1101. (Pubitemid 44116919)
184. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-1162.
185. Naucler P, Ryd W, t nberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597. (Pubitemid 47598401)
186. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772. (Pubitemid 350137476)
187. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al.; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-257.
188. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 (Suppl 10):K29-K41.
189. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007;104:232-246. (Pubitemid 46054137)
190. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005;32 (Suppl 1):S34-S42. (Pubitemid 40332587)
191. Wright TC Jr. HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 (Suppl 1):S239-S246.
192. Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007;111:1-14. (Pubitemid 46281079)
193. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women. Br J Cancer 2005;93:575-581. (Pubitemid 43080002)
194. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al.; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:765-774. (Pubitemid 43983300)
195. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi Province Cervical Cancer Screening Study: a crosssectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439-444. (Pubitemid 33033096)
196. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-474. (Pubitemid 30182883)
197. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for highrisk types of human papillomavirus: the HART study. Lancet 2003;362:1871-1876. (Pubitemid 37518501)
198. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-1577. (Pubitemid 36713784)
199. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-86. (Pubitemid 30038387)
200. Chan PK, Chang AR, Yu MY, Li WH, Chan MY, Yeung AC, Cheung TH, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int J Cancer 2010;126:297-301.
201. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, MaHC, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervicalcancer screening in five developing countries. N Engl J Med 2005;353:2158-2168.
202. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
203. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010;11:1048-1056.
204. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-935.
205. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-1622.
206. Clifford GM, Smith JS, Plummer M, Muz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
207. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China. Int J Cancer 2012;131:692-705.
208. Yip YC, Ngai KL, Vong HT, Tzang LC, Ji S, Yang M, Chan PK. Prevalence and genotype distribution of cervical human papillomavirus infection in Macao. J Med Virol 2010;82:1724-1729.
209. Hlaing T, Yip YC, Ngai KL, Vong HT, Wong SI, Ho WC, et al. Distribution of human papillomavirus genotypes among cervical intraepithelial neoplasia and invasive cancers in Macao. J Med Virol 2010;82:1600-1605.
210. Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung et al. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer 2009;125:1671-1677.
211. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, et al. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002;94:1249-1253. (Pubitemid 34993876)
212. Huang S, Afonina I, Miller BA, Beckmann AM. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int J Cancer 1997;70:408-411. (Pubitemid 27107267)
213. Wu EQ, Zhang GN, Yu XH, Ren Y, Fan Y, Wu YG, et al. Evaluation of high-risk human papillomaviruses type distribution in cervical cancer in Sichuan province of China. BMC Cancer 2008;8:202.
214. Ding DC, Hsu HC, Huang RL, Lai HC, Lin CY, Yu MH, Chu TY. Type-specific distribution of HPV along the full spectrum of cervical carcinogenesis in Taiwan: an indication of viral oncogenic potential. Eur J Obstet Gynecol Reprod Biol 2008;140:245-251.
215. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004;189:1829-1832. (Pubitemid 38657219)
216. Castle PE, Rodruez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al.; Proyecto Epidemiol̈ico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
217. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315-330. (Pubitemid 47015791)
218. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-2545.
219. Molden T, Kraus I, Karlsen F, Skomedal H, Nygd JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women 30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367-372. (Pubitemid 40270098)
220. Gupta N, Srinivasan R, Rajwanshi A. Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 2010;38: 618-623.
221. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, et al.; New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008;9:937-945.
222. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-284. (Pubitemid 32225381)
223. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-1748. (Pubitemid 28550662)
224. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-891. (Pubitemid 32594981)
225. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang SC, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997;75:1410-1416. (Pubitemid 27196859)
226. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-l̈hge A, Bergeron C, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol 2011;121:505-509.
227. Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, Czerwenka KF. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004;92:873-880. (Pubitemid 38251391)
228. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-3884. (Pubitemid 38697299)
229. Kulmala SM, Syrjen SM, Gyllensten UB, Shabalova IP, Petrovichev N, Tosi P, et al. Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 2006;59:513-517.
230. Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli MR, et al. Study of viral integration of HPV-16 in young patients with LSIL. J Clin Pathol 2003;56:532-536. (Pubitemid 36819426)
231. Cheung JL, Cheung TH, Tang JW, Chan PK. Increase of integration events and infection loads of human papillomavirus type 52 with lesion severity from low-grade cervical lesion to invasive cancer. J Clin Microbiol 2008;46:1356-1362. (Pubitemid 351563579)
232. Cheung JL, Cheung TH, Ng CW, Yu MY, Wong MC, Siu SS, et al. Analysis of human papillomavirus type 18 load and integration status from low-grade cervical lesion to invasive cervical cancer. J Clin Microbiol 2009;47:287-293.
233. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68:307-313. (Pubitemid 351380133)
234. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006;44:1755-1762. (Pubitemid 43726265)
235. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 2006;102:54-60.
236. Cheung JL, Lo KW, Cheung TH, Tang JW, Chan PK. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis 2006;194:1706-1712. (Pubitemid 44902002)
237. Chan PK, Cheung JL, Cheung TH, Lo KW, Yim SF, Siu SS, Tang JW. Profile of viral load, integration, and E2 gene disruption of HPV58 in normal cervix and cervical neoplasia. J Infect Dis 2007;196:868-875. (Pubitemid 47378936)
238. Bhattacharjee B, Sengupta S. CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2006;354:280-285. (Pubitemid 44527961)
239. Badal V, Chuang LS, Tan EH, Badal S, Villa LL, Wheeler CM, et al. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 2003;77:6227-6234. (Pubitemid 36588393)
240. Ding DC, Chiang MH, Lai HC, Hsiung CA, Hsieh CY, Chu TY. Methylation of the long control region of HPV16 is related to the severity of cervical neoplasia. Eur J Obstet Gynecol Reprod Biol 2009;147:215-220.
241. Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K, Barrera-Saldana HA, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 2004;78:12762-12772. (Pubitemid 39507784)
242. Kim K, Garner-Hamrick PA, Fisher C, Lee D, Lambert PF. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 2003;77:12450-12459. (Pubitemid 37430642)
243. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a costarican population. J Natl Cancer Inst. 2012;104:556-565.
244. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52. (Pubitemid 36124295)
245. Kjaer S, Hdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-10636. (Pubitemid 44799787)
246. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al.; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
247. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-309.
248. Cervical cytology screening. ACOG Practice Bulletin no. 109. Obstet Gynecol 2009;114:1409-20.
249. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010;134:193-199.
250. Kj SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-1488.
251. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-222. (Pubitemid 47530909)
252. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. ASCUS-LSIL Triage Study (ALTS) Group. Am J Obstet Gynecol 2003;188:1383-1392.
253. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-293. (Pubitemid 38256273)
254. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356.e1-6.
255. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24:S3/78-89.
256. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, Folicaldi S, et al.; NTCC working group. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 2007;43:476-480. (Pubitemid 46177594)
257. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92: 397-402.
258. Castle PE, Fetterman B, Thomas Cox J, Shaber R, Poitras N, Lorey T, Kinney W. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010;116:76-84.
259. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer 2006;108:298-305. (Pubitemid 44583708)
260. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115:243-248.
261. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-211. (Pubitemid 38418058)
262. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99(3 Suppl 1):S7-S11. (Pubitemid 41774340)
263. Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, et al. Human papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: The importance of a persistent viral infection. J Clin Virol 2011;52:88-92.
264. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115:1001-1007. (Pubitemid 351841763)
265. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al.; VENICE 2 project gatekeepers group. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010;15:19730.
266. European Medicines Agency. Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). Available at: http://www.emea. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/ human-med-000694. jsp&mid=WC0b01ac058001d124. Accessed on 9 July 2012.
267. European Medicines Agency. Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed). Available at: http://www.emea.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000703/human-med-000805. jsp&mid=WC0b01ac058001d124. Accessed on 9 July 2012.
268. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008;32:457-61.
269. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26 :A16-23. (Pubitemid 351312311)
270. Franceschi S, Denny L, Irwin KL, Jeronimo J, Lopalco PL, Monsonego J, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011;128:2765-2774.
271. Mayrand MH, Franco EL. Integrating novel primary-and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncol 2010;6:1725-1733.
272. Drolet M, Brisson M, Maunsell E, Franco EL, Coutl̈ F, Ferenczy A, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2011 Jun 21. doi: 10.1002/pon.2003.
273. Wardle J, Waller J, Brunswick N, Jarvis MJ. Awareness of risk factors for cancer among British adults. Public Health 2001;115:173-174. (Pubitemid 32529771)
274. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003;79:320-322. (Pubitemid 37026352)
275. Dell DL, Chen H, Ahmad F, Stewart DE. Knowledge about human papillomavirus among adolescents. Obstet Gynecol 2000; 96:653-656.
276. Anhang R, Goodman A, Goldie SJ. HPV communication: review of existing research and recommendations for patient education. CA Cancer J Clin 2004;54:248-259. (Pubitemid 39419765)